PFS Stock News & Sentiment

• The completion of the Pre-Feasibility Study establishes Defense Metals' Wicheeda Project as one of the most advanced undeveloped rare earth projects    in North America or Europe. • The Wicheeda Project economics of pre-tax NPV at 8% of US$1.8 billion and IRR of 24.6% with after-tax payback of 3.7 years are robust.

Provident Financial Services is a U.S. regional bank focused on mortgage lending in New Jersey, Pennsylvania, and New York. The bank's Q4 2024 results reflected the final costs of the merger with Lakeland Bancorp. Looking ahead to 2025, the bank expects no additional merger costs and a stable net interest margin.

Provident Financial Services, Inc. (NYSE:PFS ) Q4 2024 Results Conference Call January 29, 2025 10:00 AM ET Company Participants Adriano Duarte - Head & Investor Relations Officer Tony Labozzetta - President and Chief Executive Officer Tom Lyons - Senior Executive Vice President and Chief Financial Officer Conference Call Participants Mark Fitzgibbon - Piper Sandler Billy Young - RBC Capital Markets Tim Switzer - KBW Feddie Strickland - Hovde Group Manuel Navas - D.A. Davidson Operator Good morning, and welcome everyone to the Provident Financial Services, Inc. Fourth Quarter Earnings Conference Call.

The headline numbers for Provident Financial (PFS) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Provident Financial (PFS) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.36 per share a year ago.

ISELIN, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE:PFS) (the “Company”) reported net income of $48.5 million, or $0.37 per basic and diluted share for the three months ended December 31, 2024, compared to $46.4 million, or $0.36 per basic and diluted share, for the three months ended September 30, 2024 and $27.3 million, or $0.36 per basic and diluted share, for the three months ended December 31, 2023. For the year ended December 31, 2024, net income totaled $115.5 million, or $1.05 per basic and diluted share, compared to $128.4 million, or $1.72 per basic and $1.71 per diluted share, for the year ended December 31, 2023.

Funding is provided through the FHBNY's Small Business Recovery Grant Program Funding is provided through the FHBNY's Small Business Recovery Grant Program

Basel, 13 December 2024– Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency has approved Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet' age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect more than nine million people in the European Union (EU) and can have a devastating impact – physically, emotionally, and economically – on those affected, their families and caregivers.1-5

AbraSilver's updated PFS for Diablillos shows a 50% increase in after-tax NPV-5, mainly driven by favorable fiscal regime changes. However, the update seems to have been misunderstood by the market. The RIGI program is a boon for Diablillos economics and helps establish a timeline with a fixed deadline, with Diablillos to potentially pour first silver by 2029. Diablillos' low full-cycle cost positions it as a top-tier silver project with substantial upside potential, despite inherent risks.